GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) — Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX programs for patients with solid tumors and diseases outside oncology.
{iframe}https://finance.yahoo.com/news/arcellx-raises-85-million-series-110000355.html{/iframe}